Tests DCC-2812 in people with advanced kidney, bladder or prostate cancer
Tests the drug DCC-2812 alone in adults with advanced kidney, bladder or prostate cancer.
Plain-language title generated from the registry record
Registry title: Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Key facts
- Where
- Ann Arbor, Austin, Boston, Cleveland, Nashville, Philadelphia, San Antonio, and St Louis, United StatesSee the 8 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic kidney cancer (renal cell carcinoma), urothelial cancer, or castration-resistant prostate cancer. It tests the drug DCC-2812 alone.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced or metastatic renal cell carcinoma, urothelial cancer, or castration-resistant prostate cancer, confirmed
- Earlier treatment
- People cannot join if they had any prior anticancer therapy or investigational therapy within a set time before the first dose of DCC-2812. The record does not give the length of that time.
Main reasons for not taking part
- Any prior anticancer or investigational therapy within a set time before the first dose
- Impaired heart function
- Major surgery within 28 days of the first dose of the study drug
- Not able to take oral medication
- Organ function or electrolytes that are not adequate
Read by machine on 9 November 2026.
Where in United States
- University of MichiganAnn Arbor, United StatesTaking people
- NEXT Oncology - AustinAustin, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Cleveland ClinicCleveland, United StatesTaking people
- Vanderbilt-Ingram Cancer CenterNashville, United StatesTaking people
- Fox Chase Cancer CenterPhiladelphia, United StatesTaking people
- NEXT Oncology San AntonioSan Antonio, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Deciphera Pharmaceuticals, LLC
- Trial code
- NCT06966024
- Record updated
- 18 August 2026
- Original description
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.Read full original descriptionShow less
An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.
Inclusion: Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer; Able to take oral medication; If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements; Adequate organ function and electrolytes.
Exclusion: Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812; Major surgery within 28 days of the first dose of study drug; Impaired cardiac function.